Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009)

Market Cap	13.98B
Revenue (ttm)	2.77B
Net Income (ttm)	782.53M
Shares Out	1.67B
EPS (ttm)	0.47
PE Ratio	17.80
Forward PE	n/a
Dividend	0.25 (2.89%)
Ex-Dividend Date	n/a

Volume	6,204,560
Open	8.85
Previous Close	8.64
Day's Range	8.56 - 8.85
52-Week Range	7.41 - 11.77
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Anhui Anke Biotechnology (Group)

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 2,986
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300009

Financial Performance

In 2023, Anhui Anke Biotechnology (Group)'s revenue was 2.87 billion, an increase of 22.94% compared to the previous year's 2.33 billion. Earnings were 847.23 million, an increase of 20.47%.